Business
Novavax Reports Third Quarter 2022 Financial Results and Operational Highlights
Achieved total revenue for the third quarter of $735 million Delivered over 94 million doses of NVX-CoV2373 globally to dateAuthorized as a booster for adults
About this update from Novavax, Inc.
[{"type":"text","content":"Achieved total revenue for the third quarter of $735 million Delivered over 94 million doses of NVX-CoV2373 globally to dateAuthorized as a booster for adults in the U.S., E.U., and additional markets Authorized as a primary series for adolescents aged 12 – 17 years in U.S., EU, Japan, and additional markets Announced data about our prototype's broad immune response against circulating variants when used as a booster Initiated NVX-CoV2373 Phase 2b/3 study in children 6 months through 11 years of ageRefining full year 2022 total revenue guidance to approximately $2.0 billionCompany to host conference call today at 4:30 p.m. ETGAITHERSBURG, Md., Nov. 8, 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2022.\n\"Our progress in the third quarter continued as we successfully expanded our COVID-19 vaccine's label, achieved policy recommendations globally and expanded our body of clinical evidence supporting the differentiated benefit of our vaccine technology,\" said Stanley C. Erck, President and Chief Executive Officer, Novavax. \"New data that we announced today reaffirms the broad immune responses of NVX-CoV2373 against circulating variants. Additionally, based on our most recent Phase 1/2 trial results for our COVID-19-Influenza Combination (CIC) vaccine candidate, we look forward to initiating our Phase 2 clinical trial by the end of this year.\"\nThird Quarter 2022 and Recent Highlights\nExpanded COVID-19 Vaccine in Adult Population Aged 18 and Older\nNuvaxovid™ booster authorized for emergency use in the U.S., European Union (EU), Switzerland, United Arab Emirates (UAE) and New Zealand, with submissions completed to World Health Organization (WHO), as well as in Great Britain and South KoreaRecommendations provided by U.S. Centers for Disease Control and Prevention (CDC), E.U.'s Committee for Medicinal Products for Human Use and Switzerland's Federal Office of Public Health Nuvaxovid granted import and use permit in Israel for primary series and as a booster Covovax™ granted full product registration in South Africa for primary seriesExpanded COVID-19 Vaccine in Adolescent Population Aged 12 Thro...